ACY-1215 (Rocilinostat), HDAC6 inhibitor

Catalog No. size PriceQuantity
M60076-5S 5mg solid $109
M60076-25S 25mg solid $310


Product Information
Molecular Weight: 433.50
Formula: C24H27N5O3
Purity: ≥ 98%
CAS#: 1316214-52-4
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year
Chemical Name: 2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
Solubility: DMSO up to 100 mM


Biological Activity:

ACY-1215 (Rocilinostat) is a highly potent, selective, and orally bioavailable inhibitor of histone deacetylase 6 (HDAC6). It inhibits HDAC6 with an enzymatic IC50 ~ 5nM, and has about 10 fold selectivity against HDAC1, HDAC2, and HDAC3 (58 nM, 48 nM, 51 nM). It has minimal activity (IC50 >1 µM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2, and has slight activity against HDAC8 (IC50 ~0.1 µM). ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresome protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. Low doses of ACY-1215 combined with bortezomib triggered synergistic anti- multiple myeloma (anti-MM) activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase. In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models. Currently ACY-1215 is in phase I clinical trials in combination with Lenalidomide and Dexamethasone for patients with multiple myeloma.

How to Use:

In vitro:  ACY-1215 was used at 1 µM final concentration in vitro and in cellular assays.

In vivo: ACY-1215 was intraperitoneally dosed to mice consecutively for 5 days a week at 50 mg/kg dissolved in 5% dextrose in water with 10% DMSO or in combination with bortezomib (biweekly IV) 0.5 mg/kg dissolved in 0.9% saline solution.


  1. 1. Santo L, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. (2012) Blood. 119(11):2579-89.
  2. 2.

Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed